Create a detailed report of pfe stock with the following analysis: fundamental, technical, price action, sentiments and momentum

Pfizer Inc. (PFE) Stock Report

1. Fundamental Analysis
   • Financial Performance: Pfizer reported a diluted EPS of $0.01 and a revenue growth rate of 2.12%. The net profit margin has shown a decreasing trend, from 34.72% in Q3 2021 to 11.26% in Q2 2024.
   • Market Position: The company has a high institutional position ratio of 66.11%, indicating strong investor confidence.
   • Analyst Ratings: Pfizer has a consensus rating of "Neutral" with an average price target of $38.4, suggesting a cautious outlook from analysts.

2. Technical Analysis
   • Moving Averages: The 5-Day Moving Average (MA) is $29.34, the 10-Day MA is $29.38, and the 50-Day MA is $29.06. This indicates a short-term sideways movement with a slight uptrend potential.
   • Oscillators: The RSI is 48.07, the MACD is 0.05, and the KDJ is 23.95. These oscillators suggest that the stock is neither overbought nor oversold, indicating a balanced momentum.
   • Support and Resistance Levels: The support level is $29.08, and the resistance level is $29.37. This indicates a narrow trading range, which could lead to a breakout if either level is breached.

3. Price Action
   • Recent Performance: Pfizer's stock has experienced a decline of -2.07% compared to the previous week and -2.58% over the month. However, there has been a recent positive movement, with the stock price rising 1.9% on October 14, 2024.
   • Short Interest: There is a bearish stance on Pfizer, with a significant increase in short interest.
4. Sentiments
   • Analyst Ratings: The consensus rating is "Neutral" with price targets ranging from $27.27 to $47.25, indicating a range of potential outcomes.
   • Investor Sentiment: The sentiment is mixed, with recent positive developments such as the potential for a spin-off and a rise in the stock price, but also concerns about the company's financial situation and the impact of patent expirations.
5. Momentum
   • Price Momentum: Pfizer's stock has experienced a decline of -6.88% over the past year, which could impact its momentum going forward.
   • Earnings Momentum: The company's earnings have shown a decreasing trend, which could affect its future momentum.

In conclusion, Pfizer Inc. (PFE) demonstrates a mixed fundamental performance with a decreasing net profit margin and a cautious analyst outlook. However, the technical indicators show a balanced momentum, and the stock has recently shown some positive price action. The sentiment among analysts and investors is mixed, with both positive and negative factors at play. The company's recent developments and the broader market conditions suggest a complex outlook for Pfizer's stock.